Skip to main content

Table 3 Surgery performed in sixty patients with locally advanced breast cancer subjected to neoadjuvant chemotherapy with docetaxel and epirubicin combination.

From: HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

  OR N (%) NR N (%) P Test
Clinical Response 46 (76.7) 14 (33.3) - -
Surgery     
RS 12 (26) 7 (50)   
BCS 34 (74) 6 (42.8)   
NS 0 1 (7.2) 0.03 x 2
Node     
Median (range) 0 (0 – 19) 3 (0 – 25) 0.03 Spearman r
  1. OR = objective response; NR = no response; RS = radical surgery; BCS = breast conserving surgery; NS = not submitted to surgery.